Celgene (NASDAQ:CELG)‘s stock had its “hold” rating reiterated by stock analysts at Citigroup in a report issued on Friday.

CELG has been the subject of a number of other research reports. William Blair reissued an “outperform” rating on shares of Celgene in a research report on Friday, October 20th. BidaskClub raised shares of Celgene from a “sell” rating to a “hold” rating in a research report on Tuesday, December 12th. Leerink Swann reissued a “buy” rating and issued a $156.00 price objective on shares of Celgene in a research report on Friday, October 20th. Deutsche Bank began coverage on shares of Celgene in a research report on Tuesday, December 12th. They issued a “hold” rating and a $114.00 price objective for the company. Finally, Piper Jaffray Companies reissued a “neutral” rating and issued a $133.00 price objective on shares of Celgene in a research report on Monday, October 23rd. One investment analyst has rated the stock with a sell rating, twelve have given a hold rating, twenty-one have assigned a buy rating and one has issued a strong buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of $135.43.

Celgene (NASDAQ CELG) opened at $106.33 on Friday. The company has a debt-to-equity ratio of 1.31, a current ratio of 3.65 and a quick ratio of 3.52. The firm has a market cap of $84,935.75, a P/E ratio of 25.26, a PEG ratio of 0.84 and a beta of 1.78. Celgene has a 52-week low of $94.55 and a 52-week high of $147.17.

Celgene (NASDAQ:CELG) last posted its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $1.91 earnings per share for the quarter, beating analysts’ consensus estimates of $1.87 by $0.04. The business had revenue of $3.29 billion during the quarter, compared to analyst estimates of $3.42 billion. Celgene had a net margin of 27.36% and a return on equity of 63.80%. The company’s revenue was up 10.2% on a year-over-year basis. During the same quarter in the previous year, the business posted $1.58 earnings per share. analysts forecast that Celgene will post 6.68 EPS for the current year.

In other news, insider Terrie Curran sold 1,727 shares of the company’s stock in a transaction on Monday, September 25th. The shares were sold at an average price of $143.89, for a total value of $248,498.03. Following the completion of the transaction, the insider now directly owns 3,925 shares in the company, valued at $564,768.25. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 0.95% of the stock is currently owned by corporate insiders.

Several hedge funds have recently made changes to their positions in CELG. Capital Counsel LLC NY boosted its stake in Celgene by 0.4% during the 2nd quarter. Capital Counsel LLC NY now owns 1,649 shares of the biopharmaceutical company’s stock valued at $214,000 after acquiring an additional 6 shares during the last quarter. Fort Pitt Capital Group LLC increased its holdings in shares of Celgene by 0.6% in the 2nd quarter. Fort Pitt Capital Group LLC now owns 1,925 shares of the biopharmaceutical company’s stock worth $250,000 after acquiring an additional 11 shares during the period. South Texas Money Management Ltd. increased its holdings in shares of Celgene by 0.6% in the 1st quarter. South Texas Money Management Ltd. now owns 2,453 shares of the biopharmaceutical company’s stock worth $305,000 after acquiring an additional 15 shares during the period. Flagship Harbor Advisors LLC increased its holdings in shares of Celgene by 0.9% in the 1st quarter. Flagship Harbor Advisors LLC now owns 2,054 shares of the biopharmaceutical company’s stock worth $253,000 after acquiring an additional 18 shares during the period. Finally, Savant Capital LLC increased its holdings in shares of Celgene by 0.9% in the 2nd quarter. Savant Capital LLC now owns 2,350 shares of the biopharmaceutical company’s stock worth $305,000 after acquiring an additional 20 shares during the period. Institutional investors and hedge funds own 79.84% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Celgene (CELG) Rating Reiterated by Citigroup” was first posted by TheOlympiaReport and is owned by of TheOlympiaReport. If you are accessing this news story on another site, it was illegally copied and republished in violation of U.S. & international copyright & trademark legislation. The correct version of this news story can be read at https://theolympiareport.com/2017/12/24/celgene-celg-rating-reiterated-by-citigroup.html.

About Celgene

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Analyst Recommendations for Celgene (NASDAQ:CELG)

Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.